Rosetrees Interdisciplinary workshop on neurodegenerative diseases of the brain Feb 10, 2021 09:00 AM - 05:00 PM — Virtual Meeting (online)
iCAIRD, NHS GG&C and NVIDIA: AI in Healthcare Feb 25, 2021 09:00 AM - 12:15 PM — Virtual Meeting (online)
Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
Total Body PET 2021 conference [rescheduled] Sep 25, 2021 - Sep 27, 2021 — McEwan Hall, University of Edinburgh

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Results of the MRI Substudy of the Intravenous Magnesium Efficacy in Stroke Trial

Author(s): C. S. Kidwell, K. R. Lees, K. W. Muir, C. Chen, S. M. Davis, D. A. De Silva, C. J. Weir, S. Starkman, J. R. Alger, J. L. Saver, Mr Images Investigators

Abstract:
Background and Purpose-Although magnesium is neuroprotective in animal stroke models, no clinical benefit was confirmed in the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial of acute stroke patients. The Magnetic Resonance in IMAGES (MR IMAGES) substudy investigated the effects of magnesium on the imaging surrogate outcome of infarct growth. Methods-IMAGES trial patients in participating centers were randomized to receive either intravenous magnesium or placebo within 12 hours of stroke onset. Infarct growth was defined as volume difference between baseline diffusion-weighted imaging and day 90 fluid-attenuated inversion recovery image lesions. Patients who died were imputed the largest infarct growth observed. Results-Among the 90 patients included in the primary analysis, there was no difference in infarct growth (median absolute growth, P=0.639; median percentage growth, P=0.616; proportion with any growth, P=0.212) between the 46 treated with magnesium and 44 with placebo. Infarct growth correlated with NIHSS score change from baseline to day 90. There was a trend showing baseline serum glucose correlated with infarct growth with magnesium treatment, but not in the placebo group. The mismatch frequency was reduced from 73% to 47% by increasing the mismatch threshold from >20% to >100% of core volume. Conclusions-Infarct growth, confirmed here as a surrogate for clinical progression, was similar between magnesium and placebo treatment, paralleling the main IMAGES trial clinical outcomes. Glucose was a covariate for infarct growth with magnesium treatment. A more stringent mismatch threshold to define penumbra more appropriately would have excluded half of the patients in this 12-hour time window stroke study. (Stroke. 2009; 40: 1704-1709.)

Full version: Available here

Click the link to go to an external website with the full version of the paper


ISBN: 0039-2499
Publication Year: 2009
Periodical: Stroke
Periodical Number: 5
Volume: 40
Pages: 1704-1709
Author Address: